Researchers have found promising results in combining pembrolizumab with soluble EphB4-albumin for HPV-negative head and neck squamous cell carcinoma.
- A new study explored the combination of pembrolizumab and soluble EphB4-HSA in treating HPV-negative head and neck squamous cell carcinoma.
- The study focused on patients with relapsed or metastatic HNSCC after standard treatments had low response rates.
- The combination therapy showed a favorable safety profile and promising activity, particularly in HPV-negative/EphrinB2 positive patients with HNSCC.
- Key results included a 24% overall response rate, with higher rates in HPV-negative/EphrinB2 positive patients.
- Researchers highlighted the potential of this combination therapy to improve outcomes in patients with HPV-negative HNSCC.
Source link
Oncology, Immunology, HPV, Head & Neck Cancer